Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Neurology · Lancet Neurol · 2026-11-01

In a phase 1/2 trial in 26 males with Duchenne muscular dystrophy amenable to exon 44 skipping, adverse events occurred in 84% on del-zota vs 86% on placebo; two stopped (one anaphylaxis, one infusion reaction). Dystrophin rose about 25% with del-zota vs −0·7% with placebo.

RCTn = 26
Veerapandiyan et al. Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial
Neurology · Lancet Neurol · 2026-10-01

In 305 adults with ALS, the oral RIPK1 inhibitor SAR443820 did not slow functional decline versus placebo at 24 weeks (ALSFRS-R change −6.73 vs −6.32; difference −0.41, non-significant) and caused more discontinuations, mainly raised liver enzymes.

RCTn = 305
Cudkowicz et al. Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Neurology · Lancet Neurol · 2026-08-24

In 92 adults with narcolepsy type 1, once-daily alixorexton 4, 6 or 8 mg for 6 weeks improved Maintenance of Wakefulness Test sleep latency versus placebo by 22.2, 24.1 and 26.0 min (all adjusted p<0.01). Frequent urination (55%) and insomnia (28%) were common.

RCTn = 92
Plazzi et al. Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Neurology · Neurology · 2026-08-20

In a post hoc analysis of 550 patients with large-vessel occlusion stroke, tenecteplase before thrombectomy improved 90-day functional independence when ASPECTS was <8 (aRR 1.67) but not 8–10 (aRR 0.99), where 90-day mortality was numerically higher (aRR 1.89). Exploratory.

Secondary analysisn = 550
Huang et al. Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.